Active-Control Studies Intended to Show Equivalence in Clinical Study Report
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Explain the equivalence objective, analysis approach, margins or decision framework as applicable, and the evidence needed to interpret whether the intended comparison is supported.
Key details
Core IssueICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
Further guidance
Content
Explain the equivalence objective, analysis approach, margins or decision framework as applicable, and the evidence needed to interpret whether the intended comparison is supported.
Purpose
Explain the equivalence objective, analysis approach, margins or decision framework as applicable, and the evidence needed to interpret whether the intended comparison is supported.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 9.2 calls for discussion of the chosen control and study design, including design problems or biases that may matter for interpretation. This guide concerns the rationale and limitations of the control/design choice; the Study Design guide owns the descriptive overview of the study configuration itself.
ICH E3 section 11.4.4 addresses relationships among dose, measured drug concentration, and clinical response when those data are relevant to interpreting efficacy. This results-level relationship analysis is distinct from documenting how doses were selected or how concentrations were measured during study conduct.
ICH E3 section 9.4.3 calls for the specific method used to assign patients to treatment groups, including relevant allocation, stratification, or blocking features. This report-body method section is distinct from the detailed randomization scheme and codes placed in appendix 16.1.7 and should not imply randomization when the study used another assignment method.
ICH E3 section 11.4.2.4 addresses analysis and interpretation issues specific to multicentre studies, including centre effects and the basis for pooling centres when relevant. This is a CSR results-analysis subsection for multicentre evidence; it is not a general guide to designing or operating multicentre trials.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
